1
|
Fan D, Wu R. Mechanisms of the septic heart: From inflammatory response to myocardial edema. J Mol Cell Cardiol 2024; 195:73-82. [PMID: 39142438 DOI: 10.1016/j.yjmcc.2024.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Revised: 08/10/2024] [Accepted: 08/11/2024] [Indexed: 08/16/2024]
Abstract
Sepsis-induced myocardial dysfunction (SIMD), also known as sepsis-induced cardiomyopathy (SICM), is linked to significantly increased mortality. Despite its clinical importance, effective therapies for SIMD remain elusive, largely due to an incomplete understanding of its pathogenesis. Over the past five decades, research involving both animal models and human studies has highlighted several pathogenic mechanisms of SICM, yet many aspects remain unexplored. Initially thought to be primarily driven by inflammatory cytokines, current research indicates that these alone are insufficient for the development of cardiac dysfunction. Recent studies have brought attention to additional mechanisms, including excessive nitric oxide production, mitochondrial dysfunction, and disturbances in calcium homeostasis, as contributing factors in SICM. Emerging clinical evidence has highlighted the significant role of myocardial edema in the pathogenesis of SICM, particularly its association with cardiac remodeling in septic shock patients. This review synthesizes our current understanding of SIMD/SICM, focusing on myocardial edema's contribution to cardiac dysfunction and the critical role of the bradykinin receptor B1 (B1R) in altering myocardial microvascular permeability, a potential key player in myocardial edema development during sepsis. Additionally, this review briefly summarizes existing therapeutic strategies and their challenges and explores future research directions. It emphasizes the need for a deeper understanding of SICM to develop more effective treatments.
Collapse
Affiliation(s)
- Dihan Fan
- Psychiatric Genetics Group, McGill University, Canada
| | - Rongxue Wu
- Department of Medicine, Section of Cariology, Biological Sciences Division, The University of Chicago, IL, United States.
| |
Collapse
|
2
|
Mendes GMDM, Do Nascimento IJB, Marazzi-Diniz PHS, Da Silveira IB, Itaborahy MF, Viana LE, Silva FA, Santana MF, Pinto RAA, Dutra BG, Lacerda MVG, Araujo SA, Wanderley D, Vidigal PVT, Diniz PHC, Verano-Braga T, Santos RAS, Leite MF. The des-Arg 9-bradykinin/B1R axis: Hepatic damage in COVID-19. Front Physiol 2022; 13:1080837. [PMID: 36601349 PMCID: PMC9806358 DOI: 10.3389/fphys.2022.1080837] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Accepted: 12/06/2022] [Indexed: 12/23/2022] Open
Abstract
Patients infected by the SARS-CoV-2 virus are commonly diagnosed with threatening liver conditions associated with drug-induced therapies and systemic viral action. RNA-Seq data from cells in bronchoalveolar lavage fluid from COVID-19 patients have pointed out dysregulation of kallikrein-kinin and renin-angiotensin systems as a possible mechanism that triggers multi-organ damage away from the leading site of virus infection. Therefore, we measured the plasma concentration of biologically active peptides from the kallikrein-kinin system, bradykinin and des-Arg9-bradykinin, and liver expression of its proinflammatory axis, bradykinin 1 receptor (B1R). We measured the plasma concentration of bradykinin and des-Arg9-bradykinin of 20 virologically confirmed COVID-19 patients using a liquid chromatography-tandem mass spectrometry-based methodology. The expression of B1R was evaluated by immunohistochemistry from post-mortem liver specimens of 27 COVID-19 individuals. We found a significantly higher blood level of des-Arg9-bradykinin and a lower bradykinin concentration in patients with COVID-19 compared to a healthy, uninfected control group. We also observed increased B1R expression levels in hepatic tissues of patients with COVID-19 under all hepatic injuries analyzed (liver congestion, portal vein dilation, steatosis, and ischemic necrosis). Our data indicate that des-Arg9-bradykinin/B1R is associated with the acute hepatic dysfunction induced by the SARS-CoV-2 virus infection in the pathogenesis of COVID-19.
Collapse
Affiliation(s)
- Gabriel Moreira de M Mendes
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil,Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Israel Júnior Borges Do Nascimento
- Escola de Medicina e Hospital universitário, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil,Center for Infectious Disease Research, Medical College of Wisconsin, Milwaukee, WI, United States
| | - Paulo HS. Marazzi-Diniz
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Izabela B. Da Silveira
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil,Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Matheus F. Itaborahy
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil,Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Luiz E. Viana
- Escola de Medicina e Hospital universitário, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil,Departamento de Anatomia Patológica e Medicina Legal, Escola de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Filipe A. Silva
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | | | | | | | | | | | | | - Paula VT. Vidigal
- Departamento de Anatomia Patológica e Medicina Legal, Escola de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Paulo HC Diniz
- Departamento de Clínica Médica, Escola de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Thiago Verano-Braga
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Robson AS. Santos
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil,*Correspondence: Robson AS. Santos,
| | - M Fatima Leite
- Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| |
Collapse
|
3
|
Batista C, Sales VM, Merino VF, Bader M, Feres T, Pesquero JB. Role of Endothelial Kinin B1 Receptor on the Membrane Potential of Transgenic Rat Aorta. Physiol Res 2022. [DOI: 10.33549/physiolres.934904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
The kinin receptors are classically involved in inflammation, pain and sepsis. The effects of the kinin B1 receptor agonist des-Arg9-bradykinin (DBK) and lipopolysaccharide (LPS) were investigated by comparing the membrane potential responses of aortic rings from transgenic rats overexpressing the kinin B1 receptor (B1R) in the endothelium (TGR(Tie2B1)) and Sprague Dawley (SD) rats. No difference in the resting membrane potential in the aorta’s smooth muscle from the transgenic and SD rats was observed. The aorta rings from SD rats hyperpolarized only to LPS but not to DBK, whereas the aorta rings from TGR(Tie2B1) responded by the administration of both drugs. DBK and LPS responses were inhibited by the B1 receptor antagonist R715 and by iberiotoxin in both cases. Thapsigargin induced a hyperpolarization in the smooth muscle of SD rats that was not reversed by R715, but was reversed by iberiotoxin and this hyperpolarization was further augmented by DBK administration. These results show that the model of overexpression of vascular B1 receptors in the TGR(Tie2B1) rats represent a good model to study the role of functional B1 receptors in the absence of any pathological stimulus. The data also show that KCa channels are the final mediators of the hyperpolarizing responses to DBK and LPS. In addition, we suggest an interaction between the B1R and TLR4, since the hyperpolarization induced by LPS could be abolished in the presence of R715.
Collapse
Affiliation(s)
- C Batista
- Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil. E-mail:
| | | | | | | | | | - JB Pesquero
- Department of Biophysics, Universidade Federal de São Paulo, 04023-062, São Paulo, SP, Brazil. E-mail:
| |
Collapse
|
4
|
Tsou PS, Lu C, Gurrea-Rubio M, Muraoka S, Campbell PL, Wu Q, Model EN, Lind ME, Vichaikul S, Mattichak MN, Brodie WD, Hervoso JL, Ory S, Amarista CI, Pervez R, Junginger L, Ali M, Hodish G, O’Mara MM, Ruth JH, Robida AM, Alt AJ, Zhang C, Urquhart AG, Lawton JN, Chung KC, Maerz T, Saunders TL, Groppi VE, Fox DA, Amin MA. Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1. J Clin Invest 2022; 132:151827. [PMID: 35439173 PMCID: PMC9151693 DOI: 10.1172/jci151827] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Accepted: 04/08/2022] [Indexed: 11/17/2022] Open
Abstract
CD13, an ectoenzyme on myeloid and stromal cells, also circulates as a shed, soluble protein (sCD13) with powerful chemoattractant, angiogenic, and arthritogenic properties, which require engagement of a G protein-coupled receptor (GPCR). Here we identify the GPCR that mediates sCD13 arthritogenic actions as the bradykinin receptor B1 (B1R). Immunofluorescence and immunoblotting verified high expression of B1R in rheumatoid arthritis (RA) synovial tissue and fibroblast-like synoviocytes (FLSs), and demonstrated binding of sCD13 to B1R. Chemotaxis, and phosphorylation of Erk1/2, induced by sCD13, were inhibited by B1R antagonists. In ex vivo RA synovial tissue organ cultures, a B1R antagonist reduced secretion of inflammatory cytokines. Several mouse arthritis models, including serum transfer, antigen-induced, and local innate immune stimulation arthritis models, were attenuated in Cd13-/- and B1R-/- mice and were alleviated by B1R antagonism. These results establish a CD13/B1R axis in the pathogenesis of inflammatory arthritis and identify B1R as a compelling therapeutic target in RA and potentially other inflammatory diseases.
Collapse
Affiliation(s)
- Pei-Suen Tsou
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Chenyang Lu
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.,Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Mikel Gurrea-Rubio
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Sei Muraoka
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Phillip L. Campbell
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Qi Wu
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Ellen N. Model
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Matthew E. Lind
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Sirapa Vichaikul
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Megan N. Mattichak
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - William D. Brodie
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Jonatan L. Hervoso
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Sarah Ory
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Camila I. Amarista
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Rida Pervez
- Department of Orthopedic Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
| | - Lucas Junginger
- Department of Orthopedic Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
| | - Mustafa Ali
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Gal Hodish
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Morgan M. O’Mara
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Jeffrey H. Ruth
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | | | | | | | - Andrew G. Urquhart
- Department of Orthopedic Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
| | - Jeffrey N. Lawton
- Department of Orthopedic Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
| | - Kevin C. Chung
- Department of Orthopedic Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
| | - Tristan Maerz
- Department of Orthopedic Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
| | - Thomas L. Saunders
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.,Biomedical Research Core Facilities, Transgenic Animal Model Core, and
| | - Vincent E. Groppi
- Center for Discovery of New Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - David A. Fox
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - M. Asif Amin
- Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| |
Collapse
|
5
|
Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives. Naunyn Schmiedebergs Arch Pharmacol 2022; 395:275-283. [PMID: 35089406 PMCID: PMC8795307 DOI: 10.1007/s00210-022-02206-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2021] [Accepted: 01/17/2022] [Indexed: 12/26/2022]
Abstract
Coronavirus disease 2019 (COVID-19) is a potentially fatal disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that preferentially infects the respiratory tract. Bradykinin (BK) is a hypotensive substance that recently emerged as one of the mechanisms to explain COVID-19-related complications. Concerning this, in this review, we try to address the complex link between BK and pathophysiology of COVID-19, investigating the role of this peptide as a potential target for pharmacological modulation in the management of SARS-CoV-2. The pathology of COVID-19 may be more a result of the BK storm than the cytokine storm, and which BK imbalance is a relevant factor in the respiratory disorders caused by SARS-CoV-2 infection. Regarding this, an interesting point of intervention for this disease is to modulate BK signaling. Some drugs, such as icatibant, ecallantide, and noscapine, and even a human monoclonal antibody, lanadelumab, have been studied for their potential utility in COVID-19 by modulating BK signaling. The interaction of the BK pathway and the involvement of cytokines such as IL-6 and IL1 may be key to the use of blockers, even if only as adjuvants. In fact, reduction of BK, mainly DABK, is considered a relevant strategy to improve clinical conditions of COVID-19 patients. In this context, despite the current unproven clinical efficacy, drugs repurposing that block B1 or B2 receptor activation have gained prominence for the treatment of COVID-19 in the world.
Collapse
|
6
|
Binding Mode Exploration of B1 Receptor Antagonists' by the Use of Molecular Dynamics and Docking Simulation-How Different Target Engagement Can Determine Different Biological Effects. Int J Mol Sci 2020; 21:ijms21207677. [PMID: 33081372 PMCID: PMC7590058 DOI: 10.3390/ijms21207677] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 10/10/2020] [Accepted: 10/12/2020] [Indexed: 01/24/2023] Open
Abstract
The kinin B1 receptor plays a critical role in the chronic phase of pain and inflammation. The development of B1 antagonists peaked in recent years but almost all promising molecules failed in clinical trials. Little is known about these molecules' mechanisms of action and additional information will be necessary to exploit the potential of the B1 receptor. With the aim of contributing to the available knowledge of the pharmacology of B1 receptors, we designed and characterized a novel class of allosteric non-peptidic inhibitors with peculiar binding characteristics. Here, we report the binding mode analysis and pharmacological characterization of a new allosteric B1 antagonist, DFL20656. We analyzed the binding of DFL20656 by single point mutagenesis and radioligand binding assays and we further characterized its pharmacology in terms of IC50, B1 receptor internalization and in vivo activity in comparison with different known B1 antagonists. We highlighted how different binding modes of DFL20656 and a Merck compound (compound 14) within the same molecular pocket can affect the biological and pharmacological properties of B1 inhibitors. DFL20656, by its peculiar binding mode, involving tight interactions with N114, efficiently induced B1 receptor internalization and evoked a long-lasting effect in an in vivo model of neuropathic pain. The pharmacological characterization of different B1 antagonists highlighted the effects of their binding modes on activity, receptor occupancy and internalization. Our results suggest that part of the failure of most B1 inhibitors could be ascribed to a lack of knowledge about target function and engagement.
Collapse
|
7
|
Tamiya M, Isaka N, Kitazawa T, Hasegawa A, Ishizawa K, Ikeda M, Kawada S, Ishiguro M. Total Syntheses of the Non-Peptide Bradykinin B1 Receptor Antagonist Velutinol A and Its Analogs, seco-Pregnanes with a Cage-Like Moiety. BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN 2019. [DOI: 10.1246/bcsj.20190048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Minoru Tamiya
- Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 965-8603, Japan
| | - Nobuhisa Isaka
- Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 965-8603, Japan
| | - Takaaki Kitazawa
- Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 965-8603, Japan
| | - Atsushi Hasegawa
- Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 965-8603, Japan
| | - Kazuya Ishizawa
- Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 965-8603, Japan
| | - Mayu Ikeda
- Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 965-8603, Japan
| | - Saki Kawada
- Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 965-8603, Japan
| | - Masaji Ishiguro
- Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 965-8603, Japan
| |
Collapse
|
8
|
Shen Y, Oda T, Tamura N, Kohmura-Kobayashi Y, Furuta-Isomura N, Yaguchi C, Uchida T, Suzuki K, Itoh H, Kanayama N. Elevated bradykinin receptor type 1 expression in postpartum acute myometritis: Possible involvement in augmented interstitial edema of the atonic gravid uterus. J Obstet Gynaecol Res 2019; 45:1553-1561. [PMID: 31179603 DOI: 10.1111/jog.14012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Accepted: 05/13/2019] [Indexed: 11/29/2022]
Abstract
AIM Uterine atony is a major cause of postpartum hemorrhage. We recently proposed a new concept for the histopathophysiology of refractory uterine atony, postpartum acute myometritis (PAM), characterized by acute inflammatory changes with massive stromal edema, increased numbers of complement C5a receptors and diffuse mast cell activation in the myometrium. We herein focused on the possible involvement of the kinin-kallikrein system in the rapid development of interstitial edema in PAM, particularly bradykinin receptor type 1 (B1R), which is up-regulated under inflammatory conditions. The present study investigated B1R expression with uterine interstitial edema in PAM. METHODS Our institution plays an important role in a Japanese amniotic fluid embolism registry project. We selected PAM cases from uterine samples delivered to us for further analyses between 2012 and 2017. Control tissues were collected during cesarean section and planned hysterectomy. B1R expression was semi-quantitatively measured by immunohistochemistry, while uterine interstitial edema was estimated by semi-quantitative measurements of the alpha smooth muscle actin-negative area using immunohistochemistry. RESULTS There were 36 and 8 cases in the PAM and control groups, respectively. The alpha smooth muscle actin-negative area was increased in the PAM group, concomitant with the significant up-regulation of B1R expression in uterine smooth muscle cells, vascular endothelial cells, and neutrophils. A positive correlation was observed between these two factors. CONCLUSION We demonstrated the up-regulated expression of B1R in the myometrium and its positive correlation with histologically estimated interstitial edema, suggesting the contribution of the kinin-kallikrein-B1R system to the development of interstitial edema in PAM cases.
Collapse
Affiliation(s)
- Yi Shen
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Tomoaki Oda
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Naoaki Tamura
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yukiko Kohmura-Kobayashi
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Naomi Furuta-Isomura
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Chizuko Yaguchi
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Toshiyuki Uchida
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kazunao Suzuki
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hiroaki Itoh
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Naohiro Kanayama
- Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| |
Collapse
|
9
|
Saldanha AA, Vieira L, Ribeiro RIMDA, Thomé RG, Santos HBD, Silva DB, Carollo CA, Oliveira FMD, Lopes DDO, Siqueira JMD, Soares AC. Chemical composition and evaluation of the anti-inflammatory and antinociceptive activities of Duguetia furfuracea essential oil: Effect on edema, leukocyte recruitment, tumor necrosis factor alpha production, iNOS expression, and adenosinergic and opioidergic systems. JOURNAL OF ETHNOPHARMACOLOGY 2019; 231:325-336. [PMID: 30445104 DOI: 10.1016/j.jep.2018.11.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 11/08/2018] [Accepted: 11/08/2018] [Indexed: 06/09/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Duguetia furfuracea (A. St. -Hil.) Saff. (Annonaceae) is commonly known in Brazil as "araticum-seco," and its root is used in folk medicine to treat inflammatory and painful disorders. However, no studies have been performed to evaluate these therapeutic activities. AIM OF THE STUDY Investigate the chemical composition, anti-inflammatory and antinociceptive effects, and elucidate the possible antinociceptive mechanisms of action from the essential oil of D. furfuracea (EODf) underground stem bark. MATERIALS AND METHODS Chemical composition was determined by gas chromatography and mass spectrometry (GC/MS). The paw edema induced by LPS, formalin-induced nociception, LPS-induced thermal hyperalgesia and rota-rod tests in vivo were used to evaluate the anti-inflammatory and antinociceptive effects in addition to the alteration on motor coordination. Histological analyses and an immunohistochemistry assay for iNOS were performed on mouse footpads of naive, control, 10 mg/kg EODf, and 10 mg/kg indomethacin (Ind) groups. The samples were removed at 1, 3, and 6 h after subplantar injection of LPS. In addition, the involvement of the adenosinergic, opioidergic, serotonergic, and cholinergic systems were investigated, in order to elucidate possible antinociceptive mechanisms. RESULTS Twenty-four volatile constituents were detected and identified. (E)-asarone (21.9%), bicyclogermacrene (16.7%), 2,4,5-trimethoxystyrene (16.1%), α-gurjunene (15%), cyperene (7.8%), and (E)-caryophyllene (4.6%) were major compounds found in EODf. Oral treatment (p.o.) with EODf (1, 3, and 10 mg/kg) significantly inhibited the paw edema induced by LPS. At 10 mg/kg EODf promoted inhibition of tumor necrosis factor alpha (TNF-α) production, recruitment of polymorphonuclear (PMN) leukocytes and inducible nitric oxide synthase (iNOS) expression in paw tissue. EODf (10 and 30 mg/kg, p.o.) also reduced licking time in both phases of the formalin test and it had a significant effect on the LPS-induced thermal hyperalgesia model. The administration of caffeine (Caf) and naloxone (Nal) reversed the antinociceptive activity of EODf, in the first phase of the formalin test and in the LPS-induced thermal hyperalgesia model. Moreover, Nal was also able to abolish the antinociception caused by EODf, in the second phase of formalin test. In the rota-rod test, EODf-treated animals did not show any alteration of motor coordination. CONCLUSIONS Our findings indicate that EODf underground stem bark produces anti-inflammatory and both central and peripheral antinociceptive effects. Furthermore, the antinociceptive activity of EODf underground stem bark is possibly mediated by adenosinergic and opioidergic pathways, and its properties do not induce effects on motor coordination. These results support the use of the folk medicine, D. furfuracea root, to treat inflammation and painful conditions.
Collapse
Affiliation(s)
- Aline Aparecida Saldanha
- Laboratório de Farmacologia da Dor e Inflamação, Universidade Federal de São João del-Rei, Divinópolis 35501-296, Brazil; Laboratório de Farmacognosia/Química de Produtos Naturais, Universidade Federal de São João del-Rei, Divinópolis, Brazil
| | - Letícia Vieira
- Laboratório de Farmacologia da Dor e Inflamação, Universidade Federal de São João del-Rei, Divinópolis 35501-296, Brazil
| | | | - Ralph Gruppi Thomé
- Laboratório de Processamento de Tecidos (LAPR OTEC), Universidade Federal de São João del-Rei, Divinópolis, Brazil
| | - Hélio Batista Dos Santos
- Laboratório de Processamento de Tecidos (LAPR OTEC), Universidade Federal de São João del-Rei, Divinópolis, Brazil
| | - Denise Brentan Silva
- Laboratório de Produtos Naturais e Espectrometria de Massas (LAPNEM), Universidade Federal do Mato Grosso do Sul, Campo Grande, Brazil
| | - Carlos Alexandre Carollo
- Laboratório de Produtos Naturais e Espectrometria de Massas (LAPNEM), Universidade Federal do Mato Grosso do Sul, Campo Grande, Brazil
| | | | - Débora de Oliveira Lopes
- Laboratório de Biologia Molecular, Universidade Federal de São João del-Rei, Divinópolis, Brazil
| | - João Máximo de Siqueira
- Laboratório de Farmacognosia/Química de Produtos Naturais, Universidade Federal de São João del-Rei, Divinópolis, Brazil
| | - Adriana Cristina Soares
- Laboratório de Farmacologia da Dor e Inflamação, Universidade Federal de São João del-Rei, Divinópolis 35501-296, Brazil.
| |
Collapse
|
10
|
The serum protease network—one key to understand complex regional pain syndrome pathophysiology. Pain 2019; 160:1402-1409. [DOI: 10.1097/j.pain.0000000000001503] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
11
|
Jia M, Zhang Y, Zhang H, Qin Q, Xu CB. Cigarette Smoke Particles-Induced Airway Hyperreactivity in Vivo and in Vitro. Biol Pharm Bull 2019; 42:703-711. [PMID: 31061312 DOI: 10.1248/bpb.b18-00736] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cigarette smoke is a well-known strong risk factor for inducing airway hyperreactivity (AHR), but the underlying molecular mechanisms are not fully understood. In the present study, mouse in-vivo and in-vitro models were used to study effects of dimethyl sulfoxide (DMSO)-extracted cigarette smoke particles (DSP) on the airway, and to explore the underlying molecular mechanisms that are involved in DSP-induced AHR. In mouse in-vivo model, DSP (0.75, 1.5 or 3 µL/mL) was administered intranasally daily for 7 d. At the end of this period, lung functions were measured with flexiVent™. The results showed that the mice exhibited AHR in a dose-dependent manner following methacholine inhalation in vivo. In mouse in-vitro organ culture model, exposure of mouse tracheal segments to DSP (0.1 µL/mL) with or without the following pharmacological inhibitors: specific c-Jun-N-terminal kinase (JNK) inhibitor SP600125 (10 µM) or the anti-inflammatory drug dexamethasone (1 µM). DSP-induced bradykinin receptor-mediated airway contraction with increased mRNA and protein expressions for bradykinin B1 and B2 receptors could be significantly reduced by SP600125 or dexamethasone. In conclusion, the present study demonstrates that DSP could induce AHR in vivo and in vitro. In addition to this, the upregulation of bradykinin receptors in airway is most likely one of the underlying molecular mechanisms involved.
Collapse
Affiliation(s)
- Min Jia
- Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi'an Medical University
- Shaanxi Provincial Research Center for the Project of Prevention and Treatment of Respiratory Diseases, Xi'an Medical University
| | - Yaping Zhang
- Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi'an Medical University
| | - Han Zhang
- College of Pharmacy, Xi'an Medical University
| | - Qiaohong Qin
- Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi'an Medical University
| | - Cang-Bao Xu
- Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi'an Medical University
- Division of Experimental Vascular Research, Institute of Clinical Science in Lund, Lund University
| |
Collapse
|
12
|
Soares DDM, Santos DR, Rummel C, Ott D, Melo MCC, Roth J, Calixto JB, Souza GEP. The relevance of kalikrein-kinin system via activation of B 2 receptor in LPS-induced fever in rats. Neuropharmacology 2017; 126:84-96. [PMID: 28826826 DOI: 10.1016/j.neuropharm.2017.08.019] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Revised: 08/05/2017] [Accepted: 08/11/2017] [Indexed: 12/21/2022]
Abstract
PURPOSE This study evaluated the involvement of endogenous kallikrein-kinin system and the bradykinin (BK) B1 and B2 receptors on LPS- induced fever and the POA cells involved in this response. MATERIAL AND METHODS Male Wistar rats received either i.v. (1 mg/kg), i.c.v. (20 nmol) or i.h. (2 nmol) injections of icatibant (B2 receptor antagonist) 30 or 60 min, respectively, before the stimuli. DALBK (B1 receptor antagonist) was given either 15min before BK (i.c.v.) or 30 min before LPS (i.v.). Captopril (5 mg/kg, sc.,) was given 1 h prior LPS or BK. Concentrations of BK and total kininogenon CSF, plasma and tissue kallikrein were evaluated. Rectal temperatures (rT) were assessed by telethermometry. Ca++ signaling in POA cells was performed in rat pup brain tissue microcultures. RESULTS Icatibant reduced LPS fever while, captopril exacerbated that response, an effect abolished by icatibant. Icatibant (i.h.) reduced fever to BK (i.h.) but not that induced by LPS (i.v.). BK increased intracellular calcium concentration in neurons and astrocytes. LPS increased levels of bradykinin, tissue kallikrein and total kininogen. BK (i.c.v.) increased rT and decreased tail skin temperature. Captopril potentiated BK-induced fever an effect abolished by icatibant. DALBK reduced the fever induced by BK. BK (i.c.v.) increased the CSF PGE2concentration. Effect abolished by indomethacin (i.p.). CONCLUSIONS LPS activates endogenous kalikrein-kinin system leading to production of BK, which by acting on B2-receptors of POA cells causes prostaglandin synthesis that in turn produces fever. Thus, a kinin B2-receptor antagonist that enters into the brain could constitute a new and interesting strategy to treat fever.
Collapse
Affiliation(s)
- Denis de Melo Soares
- Department of Medicament, Faculty of Pharmacy of Federal University of Bahia, Laboratory of Pharmacology, Ribeirão Preto, SP, Brazil.
| | - Danielle R Santos
- Pharmacology, Department of Physic and Chemistry, Faculty of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - Christoph Rummel
- Veterinary Physiology, Faculty of Veterinary Medicine, Justus-Liebig-University of Giessen, Germany
| | - Daniela Ott
- Veterinary Physiology, Faculty of Veterinary Medicine, Justus-Liebig-University of Giessen, Germany
| | - Míriam C C Melo
- Pharmacology, Department of Physic and Chemistry, Faculty of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - Joachim Roth
- Veterinary Physiology, Faculty of Veterinary Medicine, Justus-Liebig-University of Giessen, Germany
| | - João B Calixto
- Center of Innovation and Preclinical Research, Florianópolis, SC, Brazil
| | - Glória E P Souza
- Pharmacology, Department of Physic and Chemistry, Faculty of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto, SP, Brazil.
| |
Collapse
|
13
|
Lupala CS, Gomez-Gutierrez P, Perez JJ. New insights into the stereochemical requirements of the bradykinin B1 receptor antagonists binding. J Mol Graph Model 2016; 68:184-196. [PMID: 27469392 DOI: 10.1016/j.jmgm.2016.06.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Revised: 06/17/2016] [Accepted: 06/17/2016] [Indexed: 02/01/2023]
Abstract
Bradykinin (BK) is a nonapeptide involved in several pathophysiological conditions including among others, septic and haemorrhagic shock, anaphylaxis, arthritis, rhinitis, asthma, inflammatory bowel disease. Accordingly, BK antagonists have long been sought after for therapeutic intervention. Action of BK is mediated through two different G-protein coupled receptors known as B1 and B2. Although there are several B1 antagonists reported in literature, their pharmacological profile is not yet optimal so that new molecules need to be discovered. In the present work we have constructed an atomistic model of the B1 receptor and docked diverse available non-peptide antagonists in order to get a deeper insight into the structure-activity relationships involving binding to this receptor. The model was constructed by homology modeling using the chemokine CXC4 and bovine rhodopsin receptors as template. The model was further refined using molecular dynamics for 600ns with the protein embedded in a POPC bilayer. From the refinement process we obtained an average structure that was used for docking studies using the Glide software. Antagonists selected for the docking studies include Compound 11, Compound 12, Chroman28, SSR240612, NPV-SAA164 and PS020990. The results of the docking study underline the role of specific receptor residues in ligand binding. The results of this study permitted to define a pharmacophore that describes the stereochemical requirements of antagonist binding, and can be used for the discovery of new compounds.
Collapse
Affiliation(s)
- Cecylia S Lupala
- Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, ETSEIB. Av. Diagonal, 647, 08028 Barcelona, Spain
| | - Patricia Gomez-Gutierrez
- Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, ETSEIB. Av. Diagonal, 647, 08028 Barcelona, Spain
| | - Juan J Perez
- Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, ETSEIB. Av. Diagonal, 647, 08028 Barcelona, Spain.
| |
Collapse
|
14
|
Matus CE, Ehrenfeld P, Pavicic F, González CB, Concha M, Bhoola KD, Burgos RA, Figueroa CD. Activation of the human keratinocyte B1 bradykinin receptor induces expression and secretion of metalloproteases 2 and 9 by transactivation of epidermal growth factor receptor. Exp Dermatol 2016; 25:694-700. [PMID: 27093919 DOI: 10.1111/exd.13038] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/11/2016] [Indexed: 12/16/2022]
Abstract
The B1 bradykinin receptor (BDKRB1) is a component of the kinin cascade localized in the human skin. Some of the effects produced by stimulation of BDKRB1 depend on transactivation of epidermal growth factor receptor (EGFR), but the mechanisms involved in this process have not been clarified yet. The primary purpose of this study was to determine the effect of a BDKRB1 agonist on wound healing in a mouse model and the migration and secretion of metalloproteases 2 and 9 from human HaCaT keratinocytes and delineate the signalling pathways that triggered their secretion. Although stimulation of BDKRB1 induces weak chemotactic migration of keratinocytes and wound closure in an in vitro scratch-wound assay, the BDKRB1 agonist improved wound closure in a mouse model. BDKRB1 stimulation triggers synthesis and secretion of both metalloproteases, effects that depend on the activity of EGFR and subsequent phosphorylation of ERK1/2 and p38 mitogen-activated protein kinases and PI3K/Akt. In the mouse model, immunoreactivity for both gelatinases was concentrated around wound borders. EGFR transactivation by BDKRB1 agonist involves Src kinases family and ADAM17. In addition to extracellular matrix degradation, metalloproteases 2 and 9 regulate cell migration and differentiation, cell functions that are associated with the role of BDKRB1 in keratinocyte differentiation. Considering that BDKRB1 is up-regulated by inflammation and/or by cytokines that are abundant in the inflammatory milieu, more stable BDKRB1 agonists may be of therapeutic value to modulate wound healing.
Collapse
Affiliation(s)
- Carola E Matus
- Instituto de Morfofisiología y Farmacología, Universidad Austral de Chile, Valdivia, Chile
| | - Pamela Ehrenfeld
- Laboratorio de Patología Celular, Instituto de Anatomía, Histología & Patología, Universidad Austral de Chile, Valdivia, Chile
| | - Francisca Pavicic
- Laboratorio de Patología Celular, Instituto de Anatomía, Histología & Patología, Universidad Austral de Chile, Valdivia, Chile
| | - Carlos B González
- Instituto de Fisiología, Universidad Austral de Chile, Valdivia, Chile
| | - Miguel Concha
- Laboratorio de Patología Celular, Instituto de Anatomía, Histología & Patología, Universidad Austral de Chile, Valdivia, Chile
| | - Kanti D Bhoola
- Laboratorio de Patología Celular, Instituto de Anatomía, Histología & Patología, Universidad Austral de Chile, Valdivia, Chile
| | - Rafael A Burgos
- Instituto de Morfofisiología y Farmacología, Universidad Austral de Chile, Valdivia, Chile
| | - Carlos D Figueroa
- Laboratorio de Patología Celular, Instituto de Anatomía, Histología & Patología, Universidad Austral de Chile, Valdivia, Chile
| |
Collapse
|
15
|
Fujimoto K, Yoshino T, Nakajima S, Yuyama H, Masuda N, Takeda M. Physiological Roles of Bradykinin and Involvement of Bradykinin B2 Receptor in Urethral Function in Humans and Animals. Low Urin Tract Symptoms 2016; 9:187-191. [PMID: 27167682 DOI: 10.1111/luts.12131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Revised: 12/25/2015] [Accepted: 01/20/2016] [Indexed: 11/30/2022]
Abstract
OBJECTIVE We investigated the role of bradykinin in urethral function by examining contractile responses in urethral smooth muscle strips isolated from humans and the intraurethral pressure in rats and dogs. METHODS The contractile responses of human urethral tissue for bradykinin (0.01-10 µmol/L) were examined, and changes in intraurethral pressure induced by bradykinin (0.003-10 µg/kg) in anesthetized rats or dogs were measured. In addition, the effects of pretreatment with the bradykinin B2 receptor antagonist FK3657 were also examined. RESULTS In smooth muscle strips obtained from human urethra, bradykinin induced contraction, which was inhibited by FK3657 in a concentration-dependent manner. In anesthetized rats and dogs, intravenously administered bradykinin dose-dependently increased intraurethral pressure. FK3657 shifted the intraurethral pressure dose-response curve for bradykinin to the right in rats. The bradykinin-induced elevation of intraurethral pressure was also dose-dependently inhibited by FK3657 in dogs. CONCLUSIONS The present study provides evidence that bradykinin elicits urethral smooth muscle contraction via the bradykinin B2 receptor, suggesting the potential utility of this receptor as a novel target for the treatment of voiding dysfunction.
Collapse
Affiliation(s)
| | - Taiji Yoshino
- Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
| | - Satoko Nakajima
- Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
| | - Hironori Yuyama
- Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
| | - Noriyuki Masuda
- Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
| | - Masahiro Takeda
- Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
| |
Collapse
|
16
|
Fujimoto K, Yoshino T, Yoshioka K, Yuyama H, Masuda N, Takeda M. Intratesticular Bradykinin Involvement in Rat Testicular Pain Models. Low Urin Tract Symptoms 2016; 10:101-105. [PMID: 27167873 DOI: 10.1111/luts.12133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Revised: 01/12/2016] [Accepted: 01/31/2016] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To clarify the role of bradykinin in urogenital pain, we investigated bradykinin involvement in rat models of testicular pain. METHODS Bradykinin (0.1, 0.3, 1, 3 and 10 mmol/L) or distilled water was injected into the testes of male Wistar rats, and induced pain behaviors in conscious rats were evaluated. The effect of pretreatment with bradykinin B2 receptor antagonist FK3657 on bradykinin-induced pain behavior was then examined. We also evaluated the analgesic effect of FK3657 in a rat acetic acid-induced testicular pain as well as changes in the intratesticular bradykinin concentration after testicular injection of acetic acid. RESULTS An injection of bradykinin into the testes of conscious rats induced pain behaviors that were dose-proportionally reduced by prior administration of FK3657. In addition, FK3657 dose-dependently inhibited the pain responses induced by testicular injection of 1% acetic acid. An increase in intratesticular bradykinin concentration was detected after the testicular injection of 1% acetic acid. CONCLUSIONS Here, we found that intratesticular bradykinin evokes pain behavior via stimulation of bradykinin B2 receptors and that intratesticular acetic acid injection induces intratesticular bradykinin synthesis, consequently leading to pain behavior. These findings suggest that the potential utility of bradykinin B2 receptor antagonists as a novel target for treating urogenital pain.
Collapse
Affiliation(s)
| | - Taiji Yoshino
- Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
| | | | - Hironori Yuyama
- Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
| | - Noriyuki Masuda
- Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
| | - Masahiro Takeda
- Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
| |
Collapse
|
17
|
Maria AG, Dillenburg-Pilla P, Reis RI, Floriano EM, Tefé-Silva C, Ramos SG, Pesquero JB, Nahmias C, Costa-Neto CM. Host kinin B1 receptor plays a protective role against melanoma progression. Sci Rep 2016; 6:22078. [PMID: 26898917 PMCID: PMC4761993 DOI: 10.1038/srep22078] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Accepted: 02/05/2016] [Indexed: 01/06/2023] Open
Abstract
Melanoma is a very aggressive tumor that arises from melanocytes. Late stage and widely spread diseases do not respond to standard therapeutic approaches. The kallikrein-kinin system (KKS) participates in biological processes such as vasodilatation, pain and inflammatory response. However, the role of KKS in tumor formation and progression is not completely understood. The role of the host kinin B1 receptor in melanoma development was evaluated using a syngeneic melanoma model. Primary tumors and metastasis were respectively induced by injecting B16F10 melanoma cells, which are derived from C57BL/6 mice, subcutaneously or in the tail vein in wild type C57BL/6 and B1 receptor knockout mice (B1−/−). Tumors developed in B1−/− mice presented unfavorable prognostic factors such as increased incidence of ulceration, higher levels of IL-10, higher activation of proliferative pathways such as ERK1/2 and Akt, and increased mitotic index. Furthermore, in the metastasis model, B1−/− mice developed larger metastatic colonies in the lung and lower CD8+immune effector cells when compared with WT animals. Altogether, our results provide evidences that B1−/− animals developed primary tumors with multiple features associated with poor prognosis and unfavorable metastatic onset, indicating that the B1 receptor may contribute to improve the host response against melanoma progression.
Collapse
Affiliation(s)
- Andrea G Maria
- Department of Biochemistry and Immunology; Ribeirão Preto Medical School - University of São Paulo, 14049-900, Ribeirão Preto, Brazil
| | - Patrícia Dillenburg-Pilla
- Department of Biochemistry and Immunology; Ribeirão Preto Medical School - University of São Paulo, 14049-900, Ribeirão Preto, Brazil
| | - Rosana I Reis
- Department of Biochemistry and Immunology; Ribeirão Preto Medical School - University of São Paulo, 14049-900, Ribeirão Preto, Brazil
| | - Elaine M Floriano
- Departament of Pathology, Ribeirão Preto Medical School - University of São Paulo, 14049-900, Ribeirão Preto, Brazil
| | - Cristiane Tefé-Silva
- Departament of Pathology, Ribeirão Preto Medical School - University of São Paulo, 14049-900, Ribeirão Preto, Brazil
| | - Simone G Ramos
- Departament of Pathology, Ribeirão Preto Medical School - University of São Paulo, 14049-900, Ribeirão Preto, Brazil
| | - João B Pesquero
- Department of Biophysics, Federal University of São Paulo, 04039-032, São Paulo, Brazil
| | - Clara Nahmias
- Inserm U981,Institut Gustave Roussy, 94800, Villejuif, France
| | - Claudio M Costa-Neto
- Department of Biochemistry and Immunology; Ribeirão Preto Medical School - University of São Paulo, 14049-900, Ribeirão Preto, Brazil
| |
Collapse
|
18
|
Effect of inflammatory mediators on ATP release of human urothelial RT4 cells. BIOMED RESEARCH INTERNATIONAL 2014; 2014:182862. [PMID: 24839598 PMCID: PMC4009244 DOI: 10.1155/2014/182862] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Accepted: 04/02/2014] [Indexed: 12/24/2022]
Abstract
Inflammation is an important contributor to the aetiology of a number of bladder dysfunctions including interstitial cystitis, painful bladder syndrome, and overactive bladder. The aim of this study was to examine the effects of inflammatory mediators on urothelial ATP release. Human urothelial RT4 cells were exposed to normal buffer or varying concentrations of inflammatory mediators (bradykinin, histamine, and serotonin) in the presence or absence of hypotonic stretch stimuli (1 : 2 dilution of Krebs-Henseleit buffer). Others have demonstrated that bradykinin increased stretch-induced ATP release; however, we observed no change in control or stretch-induced ATP release with bradykinin. Pretreatment of RT4 cells with histamine or serotonin decreased stretch-induced ATP release (P = 0.037, P = 0.040, resp.). Previous studies have demonstrated increased ATP release in response to inflammation utilising whole bladder preparations in contrast to our simple model of cultured urothelial cells. The current study suggests that it is unlikely that there is a direct interaction between the release of inflammatory mediators and increased ATP release, but rather more complex interactions occurring in response to inflammation that lead to increased bladder sensation.
Collapse
|
19
|
Marketou ME, Kontaraki J, Zacharis E, Parthenakis F, Maragkoudakis S, Gavras I, Gavras H, Vardas PE. Differential gene expression of bradykinin receptors 1 and 2 in peripheral monocytes from patients with essential hypertension. J Hum Hypertens 2014; 28:450-5. [PMID: 24401952 DOI: 10.1038/jhh.2013.133] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2013] [Revised: 11/07/2013] [Accepted: 11/19/2013] [Indexed: 12/26/2022]
Abstract
Bradykinin participates in various hypertensive processes, exerted via its type 1 and type 2 receptors (BKR1 and BKR2). The aim of the study was to investigate BKR1 and BK2R gene expression in peripheral monocytes in patients with essential hypertension compared with healthy individuals. Seventeen hypertensive patients (9 males, age 56 ± 7 years) and 12 healthy individuals (7 males, age 55 ± 6) participated. Mononuclear cells isolated using anti-CD14+ antibodies and mRNAs of BKR1 and BKR2 were estimated by real-time quantitative reverse transcription-PCR. Both BKR1 and BKR2 showed significantly upregulated gene expression in the group of hypertensive patients. Specifically, BKR1 gene expression was 142.1 ± 42.2 in hypertensives versus 20.2 ± 8 in controls (P = 0.024) and BKR2 was 1222.2 ± 361.6 in hypertensives versus 259.5 ± 99.1 in controls (P = 0.038). Antihypertensive treatment resulted in a decrease in BKR1 (from 142.1 ± 42.2 to 55.2 ± 17.1, P = 0.065) and in BKR2 (from 1222.2 ± 361.6 to 256.8 ± 81.8, P = 0.014) gene expression. BKR1 and BKR2 gene expression on peripheral monocytes is upregulated in essential hypertension. This may lead to functional changes in monocytes and contribute to the development of target organ damage in hypertensive patients.
Collapse
Affiliation(s)
- M E Marketou
- Cardiology Department, Heraklion University Hospital, Crete, Greece
| | - J Kontaraki
- Cardiology Department, Heraklion University Hospital, Crete, Greece
| | - E Zacharis
- Cardiology Department, Heraklion University Hospital, Crete, Greece
| | - F Parthenakis
- Cardiology Department, Heraklion University Hospital, Crete, Greece
| | - S Maragkoudakis
- Cardiology Department, Heraklion University Hospital, Crete, Greece
| | - I Gavras
- Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
| | - H Gavras
- Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
| | - P E Vardas
- Cardiology Department, Heraklion University Hospital, Crete, Greece
| |
Collapse
|
20
|
Petho G, Reeh PW. Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. Physiol Rev 2013; 92:1699-775. [PMID: 23073630 DOI: 10.1152/physrev.00048.2010] [Citation(s) in RCA: 191] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Peripheral mediators can contribute to the development and maintenance of inflammatory and neuropathic pain and its concomitants (hyperalgesia and allodynia) via two mechanisms. Activation or excitation by these substances of nociceptive nerve endings or fibers implicates generation of action potentials which then travel to the central nervous system and may induce pain sensation. Sensitization of nociceptors refers to their increased responsiveness to either thermal, mechanical, or chemical stimuli that may be translated to corresponding hyperalgesias. This review aims to give an account of the excitatory and sensitizing actions of inflammatory mediators including bradykinin, prostaglandins, thromboxanes, leukotrienes, platelet-activating factor, and nitric oxide on nociceptive primary afferent neurons. Manifestations, receptor molecules, and intracellular signaling mechanisms of the effects of these mediators are discussed in detail. With regard to signaling, most data reported have been obtained from transfected nonneuronal cells and somata of cultured sensory neurons as these structures are more accessible to direct study of sensory and signal transduction. The peripheral processes of sensory neurons, where painful stimuli actually affect the nociceptors in vivo, show marked differences with respect to biophysics, ultrastructure, and equipment with receptors and ion channels compared with cellular models. Therefore, an effort was made to highlight signaling mechanisms for which supporting data from molecular, cellular, and behavioral models are consistent with findings that reflect properties of peripheral nociceptive nerve endings. Identified molecular elements of these signaling pathways may serve as validated targets for development of novel types of analgesic drugs.
Collapse
Affiliation(s)
- Gábor Petho
- Pharmacodynamics Unit, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs, Pécs, Hungary
| | | |
Collapse
|
21
|
Pouliot M, Talbot S, Sénécal J, Dotigny F, Vaucher E, Couture R. Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats. PLoS One 2012; 7:e33864. [PMID: 22470485 PMCID: PMC3314679 DOI: 10.1371/journal.pone.0033864] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2011] [Accepted: 02/18/2012] [Indexed: 12/19/2022] Open
Abstract
PURPOSE Kinin B(1) receptor (B(1)R) is upregulated in retina of Streptozotocin (STZ)-diabetic rats and contributes to vasodilation of retinal microvessels and breakdown of the blood-retinal barrier. Systemic treatment with B(1)R antagonists reversed the increased retinal plasma extravasation in STZ rats. The present study aims at determining whether ocular application of a water soluble B(1)R antagonist could reverse diabetes-induced retinal inflammation and oxidative stress. METHODS Wistar rats were made diabetic with STZ (65 mg/kg, i.p.) and 7 days later, they received one eye drop application of LF22-0542 (1% in saline) twice a day for a 7 day-period. The impact was determined on retinal vascular permeability (Evans blue exudation), leukostasis (leukocyte infiltration using Fluorescein-isothiocyanate (FITC)-coupled Concanavalin A lectin), retinal mRNA levels (by qRT-PCR) of inflammatory (B(1)R, iNOS, COX-2, ICAM-1, VEGF-A, VEGF receptor type 2, IL-1β and HIF-1α) and anti-inflammatory (B(2)R, eNOS) markers and retinal level of superoxide anion (dihydroethidium staining). RESULTS Retinal plasma extravasation, leukostasis and mRNA levels of B(1)R, iNOS, COX-2, VEGF receptor type 2, IL-1β and HIF-1α were significantly increased in diabetic retinae compared to control rats. All these abnormalities were reversed to control values in diabetic rats treated with LF22-0542. B(1)R antagonist also significantly inhibited the increased production of superoxide anion in diabetic retinae. CONCLUSION B(1)R displays a pathological role in the early stage of diabetes by increasing oxidative stress and pro-inflammatory mediators involved in retinal vascular alterations. Hence, topical application of kinin B(1)R antagonist appears a highly promising novel approach for the treatment of diabetic retinopathy.
Collapse
Affiliation(s)
- Mylène Pouliot
- École d'optométrie, Université de Montréal, Montréal, Canada
- Département de Physiologie, Faculté de Médecine, Université de Montréal, Montréal, Canada
| | - Sébastien Talbot
- Département de Physiologie, Faculté de Médecine, Université de Montréal, Montréal, Canada
| | - Jacques Sénécal
- Département de Physiologie, Faculté de Médecine, Université de Montréal, Montréal, Canada
| | | | - Elvire Vaucher
- École d'optométrie, Université de Montréal, Montréal, Canada
| | - Réjean Couture
- Département de Physiologie, Faculté de Médecine, Université de Montréal, Montréal, Canada
- * E-mail:
| |
Collapse
|
22
|
Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency. Bioorg Med Chem Lett 2012; 22:1061-7. [DOI: 10.1016/j.bmcl.2011.11.112] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2011] [Revised: 11/23/2011] [Accepted: 11/28/2011] [Indexed: 11/23/2022]
|
23
|
Abstract
Akita mice have type 1 diabetes mellitus caused by a spontaneous point mutation in the Ins2 gene which leads to misfolding of insulin, resulting in pancreatic β-cell failure. Akita mice develop pronounced and sustained hyperglycemia, high levels of albuminuria, and consistent histopathological changes, suggesting that these mice may be suitable as an experimental platform for modeling diabetic nephropathy. One key feature of diabetic kidney disease in Akita mice is that the severity of renal injury is significantly influenced by genetic background. In this chapter, we describe the Akita model and present some of the experimental studies utilizing Akita mice as a model of type 1 diabetes. For example, deficiency in bradykinin receptors, endothelial nitric oxide synthase, or angiotensin-converting enzyme 2 leads to development of functionally and structurally more advanced diabetic nephropathy in these mice, while ketogenic diet has been shown to reverse kidney injury associated with diabetes. This chapter also describes the application of 24-h urine collections from mice for careful measurement of urinary albumin excretion.
Collapse
|
24
|
Isaka N, Tamiya M, Hasegawa A, Ishiguro M. A Concise Total Synthesis of the Non-peptide Bradykinin B1 Receptor Antagonist Velutinol A. European J Org Chem 2011. [DOI: 10.1002/ejoc.201101728] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
25
|
Biswas K, Peterkin TAN, Bryan MC, Arik L, Lehto SG, Sun H, Hsieh FY, Xu C, Fremeau RT, Allen JR. Discovery of Potent, Orally Bioavailable Phthalazinone Bradykinin B1 Receptor Antagonists. J Med Chem 2011; 54:7232-46. [DOI: 10.1021/jm200808v] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Kaustav Biswas
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Tanya A. N. Peterkin
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Marian C. Bryan
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Leyla Arik
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Sonya G. Lehto
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Hong Sun
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Feng-Yin Hsieh
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Cen Xu
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Robert T. Fremeau
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Jennifer R. Allen
- Departments of †Chemistry Research and Discovery, ‡Pharmacokinetics and Drug Metabolism, and §Neuroscience Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|
26
|
Hillmeister P, Gatzke N, Dülsner A, Bader M, Schadock I, Hoefer I, Hamann I, Infante-Duarte C, Jung G, Troidl K, Urban D, Stawowy P, Frentsch M, Li M, Nagorka S, Wang H, Shi Y, le Noble F, Buschmann I. Arteriogenesis Is Modulated By Bradykinin Receptor Signaling. Circ Res 2011; 109:524-33. [DOI: 10.1161/circresaha.111.240986] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Rationale:
Positive outward remodeling of pre-existing collateral arteries into functional conductance arteries, arteriogenesis, is a major endogenous rescue mechanism to prevent cardiovascular ischemia. Collateral arterial growth is accompanied by expression of kinin precursor. However, the role of kinin signaling via the kinin receptors (B1R and B2R) in arteriogenesis is unclear.
Objective:
The purpose of this study was to elucidate the functional role and mechanism of bradykinin receptor signaling in arteriogenesis.
Methods and Results:
Bradykinin receptors positively affected arteriogenesis, with the contribution of B1R being more pronounced than B2R. In mice, arteriogenesis upon femoral artery occlusion was significantly reduced in B1R mutant mice as evidenced by reduced microspheres and laser Doppler flow perfusion measurements. Transplantation of wild-type bone marrow cells into irradiated B1R mutant mice restored arteriogenesis, whereas bone marrow chimeric mice generated by reconstituting wild-type mice with B1R mutant bone marrow showed reduced arteriogenesis after femoral artery occlusion. In the rat brain 3-vessel occlusion arteriogenesis model, pharmacological blockade of B1R inhibited arteriogenesis and stimulation of B1R enhanced arteriogenesis. In the rat, femoral artery ligation combined with arterial venous shunt model resulted in flow-driven arteriogenesis, and treatment with B1R antagonist R715 decreased vascular remodeling and leukocyte invasion (monocytes) into the perivascular tissue. In monocyte migration assays, in vitro B1R agonists enhanced migration of monocytes.
Conclusions:
Kinin receptors act as positive modulators of arteriogenesis in mice and rats. B1R can be blocked or therapeutically stimulated by B1R antagonists or agonists, respectively, involving a contribution of peripheral immune cells (monocytes) linking hemodynamic conditions with inflammatory pathways.
Collapse
Affiliation(s)
- Philipp Hillmeister
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Nora Gatzke
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - André Dülsner
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Michael Bader
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Ines Schadock
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Imo Hoefer
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Isabell Hamann
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Carmen Infante-Duarte
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Georg Jung
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Kerstin Troidl
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Daniel Urban
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Philipp Stawowy
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Marco Frentsch
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Meijing Li
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Stephanie Nagorka
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Haitao Wang
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Yu Shi
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Ferdinand le Noble
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| | - Ivo Buschmann
- From the Experimental and Clinical Research Center of the Charite and the Max Delbrueck Center for Molecular Medicine (P.H., A.D., M.L., H.W., Y.S., F.l.N., I.B.), Berlin, Germany; Center for Cardiovascular Research (P.H., N.G., A.D., M.L., S.N., I.B.), Charité, Berlin, Germany; Center for Stroke Research Berlin (P.H., F.l.N., I.B.), Charité, Berlin, Germany; Experimental Neuroimmunology (I.H., C.I.D.), Max Delbrueck Center (M.B., I.S.), Berlin, Germany; Department of Experimental Cardiology (I.H.),
| |
Collapse
|
27
|
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation. Bioorg Med Chem Lett 2011; 21:3384-9. [DOI: 10.1016/j.bmcl.2011.03.115] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2011] [Revised: 03/28/2011] [Accepted: 03/31/2011] [Indexed: 11/20/2022]
|
28
|
Modulation of retinal blood flow by kinin B₁ receptor in Streptozotocin-diabetic rats. Exp Eye Res 2011; 92:482-9. [PMID: 21420952 DOI: 10.1016/j.exer.2011.03.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2010] [Revised: 02/22/2011] [Accepted: 03/08/2011] [Indexed: 11/20/2022]
Abstract
The vasoactive kinin B₁ receptor (B₁R) is overexpressed in the retina of diabetic rats in response to hyperglycemia and oxidative stress. The aim of the present study was to determine whether B₁R could contribute to the early retinal blood flow changes occurring in diabetes. Male Wistar rats were rendered diabetic with a single i.p. injection of Streptozotocin (STZ) and studied 4 days or 6 weeks after diabetes induction. The presence of B₁R in the retina was confirmed by Western blot. The impact of oral administration of the B₁R selective antagonist SSR240612 (10mg/kg) was measured on alteration of retinal perfusion in awake diabetic rats by quantitative autoradiography. Data showed that B₁R was upregulated in the STZ-diabetic retina at 4 days and 6 weeks. Retinal blood flow was not altered in 4-day diabetic rats compared with age-matched controls but was significantly decreased following SSR240612 treatment. In 6-week diabetic rats, retinal blood flow was markedly reduced compared to control rats and SSR240612 did not further decrease the blood flow. These results suggest that B₁R is upregulated in STZ-diabetic retina and has a protective compensatory role on retinal microcirculation at 4 days but not at 6 weeks following diabetes induction.
Collapse
|
29
|
Yoke Keong Y, Arifah AK, Sukardi S, Roslida AH, Somchit MN, Zuraini A. Bixa orellana leaves extract inhibits bradykinin-induced inflammation through suppression of nitric oxide production. Med Princ Pract 2011; 20:142-6. [PMID: 21252569 DOI: 10.1159/000319907] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2009] [Accepted: 05/13/2010] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE The present study was conducted to assess the anti-inflammatory effect of a crude aqueous extract of Bixa orellana leaves (AEBO) and to examine the possible involvement of nitric oxide (NO) in its anti-inflammatory mechanism. MATERIALS AND METHODS The air-dried, powdered leaves were soaked in distilled water (1:20 w/v) at 50°C for 24 h and the supernatant obtained was freeze-dried (yield 8.5% w/w). The dosage was recorded as the mass of extract per kg b.w. of rats in all inflammatory assays (bradykinin-induced paw edema, peritoneal vascular permeability and NO assay). RESULTS Pretreatment with AEBO for 4 consecutive days exhibited significant inhibitory activity against inflammatory models, the bradykinin-induced hind paw edema model and bradykinin-induced increased peritoneal vascular permeability at both doses in dose-dependent manner. In addition, AEBO was also found to significantly suppress the production of NO at doses of 50 and 150 mg/kg. CONCLUSION This study provides scientific data to support the traditional use of B. orellana leaves in treating inflammation. Results from this study suggest that AEBO exerts anti-inflammatory effects. Part of this anti-inflammatory effect may be associated with its antibradykinin activity and may be related to a reduction of the NO production.
Collapse
Affiliation(s)
- Y Yoke Keong
- Department of Biomedical Sciences, Universiti Putra Malaysia, Serdang, Malaysia
| | | | | | | | | | | |
Collapse
|
30
|
Abstract
Numerous neuropeptide/receptor systems including vasoactive intestinal polypeptide, pituitary adenylate cyclase-activating polypeptide, calcitonin gene-related peptide, substance P, neurokinin A, bradykinin, and endothelin-1 are expressed in the lower urinary tract (LUT) in both neural and nonneural (e.g., urothelium) components. LUT neuropeptide immunoreactivity is present in afferent and autonomic efferent neurons innervating the bladder and urethra and in the urothelium of the urinary bladder. Neuropeptides have tissue-specific distributions and functions in the LUT and exhibit neuroplastic changes in expression and function with LUT dysfunction following neural injury, inflammation, and disease. LUT dysfunction with abnormal voiding, including urinary urgency, increased voiding frequency, nocturia, urinary incontinence, and pain, may reflect a change in the balance of neuropeptides in bladder reflex pathways. LUT neuropeptide/receptor systems may represent potential targets for therapeutic intervention.
Collapse
|
31
|
Huang H, Player MR. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. J Med Chem 2010; 53:5383-99. [PMID: 20369879 DOI: 10.1021/jm1000776] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Hui Huang
- Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania 19477-0776, USA
| | | |
Collapse
|
32
|
Voss MJ, Entschladen F. Tumor interactions with soluble factors and the nervous system. Cell Commun Signal 2010; 8:21. [PMID: 20822525 PMCID: PMC2942890 DOI: 10.1186/1478-811x-8-21] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2010] [Accepted: 09/07/2010] [Indexed: 12/16/2022] Open
Abstract
In the genomic era of cancer research, the development of metastases has been attributed to mutations in the tumor that enable the cells to migrate. However, gene analyses revealed that primary tumors and metastases were in some cases genetically identical and the question was raised whether metastasis formation might be an inherent feature of certain tumor cells. In contradiction to this view, the last decade of cancer research has brought to light, that tumor cell migration, similar to leukocyte and fibroblast migration, is a highly regulated process. The nervous system plays an important role in this regulation, at least in two respects: firstly, neurotransmitters are known to regulate the migratory activity of tumor cells, and secondly, nerve fibers are used as routes for perineural invasion. We also summarize here the current knowledge on the innervation of tumors. Such a process might establish a neuro-neoplastic synapse, with the close interaction of tumor cells and nerve cells supporting metastasis formation.
Collapse
Affiliation(s)
- Melanie J Voss
- Institute of Immunology, ZBAF, Witten/Herdecke University, Stockumer Str, 10, 58448 Witten, Germany.
| | | |
Collapse
|
33
|
Rochat SÃ, Gao J, Qian X, Zaubitzer F, Severin K. Cross-Reactive Sensor Arrays for the Detection of Peptides in Aqueous Solution by Fluorescence Spectroscopy. Chemistry 2010; 16:104-13. [DOI: 10.1002/chem.200902202] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
34
|
Clapp C, Thebault S, Jeziorski MC, Martínez De La Escalera G. Peptide hormone regulation of angiogenesis. Physiol Rev 2009; 89:1177-215. [PMID: 19789380 DOI: 10.1152/physrev.00024.2009] [Citation(s) in RCA: 121] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
It is now apparent that regulation of blood vessel growth contributes to the classical actions of hormones on development, growth, and reproduction. Endothelial cells are ideally positioned to respond to hormones, which act in concert with locally produced chemical mediators to regulate their growth, motility, function, and survival. Hormones affect angiogenesis either directly through actions on endothelial cells or indirectly by regulating proangiogenic factors like vascular endothelial growth factor. Importantly, the local microenvironment of endothelial cells can determine the outcome of hormone action on angiogenesis. Members of the growth hormone/prolactin/placental lactogen, the renin-angiotensin, and the kallikrein-kinin systems that exert stimulatory effects on angiogenesis can acquire antiangiogenic properties after undergoing proteolytic cleavage. In view of the opposing effects of hormonal fragments and precursor molecules, the regulation of the proteases responsible for specific protein cleavage represents an efficient mechanism for balancing angiogenesis. This review presents an overview of the actions on angiogenesis of the above-mentioned peptide hormonal families and addresses how specific proteolysis alters the final outcome of these actions in the context of health and disease.
Collapse
Affiliation(s)
- Carmen Clapp
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, Mexico.
| | | | | | | |
Collapse
|
35
|
Duchene J, Ahluwalia A. The kinin B(1) receptor and inflammation: new therapeutic target for cardiovascular disease. Curr Opin Pharmacol 2009; 9:125-31. [PMID: 19124274 DOI: 10.1016/j.coph.2008.11.011] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2008] [Revised: 11/18/2008] [Accepted: 11/19/2008] [Indexed: 01/06/2023]
Abstract
The kinin B(1) receptor plays an important role in mediating the inflammatory effects of the kallikrein-kinin pathway. The recent development of orally available non-peptidic antagonists and genetically modified mice deficient in B(1) receptor expression have demonstrated that the receptor plays a pivotal role in the cellular, particularly neutrophil, recruitment associated with an acute inflammatory response. These tools have also enabled elucidation of the pathways involved in mediating this effect and have highlighted a major role for chemokines, particularly CXCL5 and CCL2. Neutrophil recruitment is involved in the pathogenesis of renal disease and has very recently been implicated in the early stages of atherosclerosis. In this review we discuss the most recent evidence linking the B(1) receptor with the pathogenesis of these two inflammatory cardiovascular diseases and highlight the therapeutic potential of the kinin B(1) receptor in these disease states.
Collapse
Affiliation(s)
- Johan Duchene
- The William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom.
| | | |
Collapse
|
36
|
Bertram CM, Misso NL, Fogel-Petrovic M, Figueroa CD, Foster PS, Thompson PJ, Bhoola KD. Expression of kinin receptors on eosinophils: comparison of asthmatic patients and healthy subjects. J Leukoc Biol 2008; 85:544-52. [DOI: 10.1189/jlb.0508283] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
37
|
Dos Santos AC, Roffê E, Arantes RME, Juliano L, Pesquero JL, Pesquero JB, Bader M, Teixeira MM, Carvalho-Tavares J. Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice. J Neuroinflammation 2008; 5:49. [PMID: 18986535 PMCID: PMC2596102 DOI: 10.1186/1742-2094-5-49] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2008] [Accepted: 11/05/2008] [Indexed: 01/11/2023] Open
Abstract
Background Kinins are important mediators of inflammation and act through stimulation of two receptor subtypes, B1 and B2. Leukocyte infiltration contributes to the pathogenesis of autoimmune inflammation in the central nervous system (CNS), occurring not only in multiple sclerosis (MS) but also in experimental autoimmune encephalomyelitis (EAE). We have previously shown that the chemokines CCL2 and CCL5 play an important role in the adhesion of leukocytes to the brain microcirculation in EAE. The aim of the present study was to evaluate the relevance of B2 receptors to leukocyte-endothelium interactions in the cerebral microcirculation, and its participation in CNS inflammation in the experimental model of myelin-oligodendrocyte-glycoprotein (MOG)35–55-induced EAE in mice. Methods In order to evaluate the role of B2 receptor in the cerebral microvasculature we used wild-type (WT) and kinin B2 receptor knockout (B2-/-) mice subjected to MOG35–55-induced EAE. Intravital microscopy was used to investigate leukocyte recruitment on pial matter vessels in B2-/- and WT EAE mice. Histological documentation of inflammatory infiltrates in brain and spinal cords was correlated with intravital findings. The expression of CCL5 and CCL2 in cerebral tissue was assessed by ELISA. Results Clinical parameters of disease were reduced in B2-/- mice in comparison to wild type EAE mice. At day 14 after EAE induction, there was a significant decrease in the number of adherent leukocytes, a reduction of cerebral CCL5 and CCL2 expressions, and smaller inflammatory and degenerative changes in B2-/- mice when compared to WT. Conclusion Our results suggest that B2 receptors have two major effects in the control of EAE severity: (i) B2 regulates the expression of chemokines, including CCL2 and CCL5, and (ii) B2 modulates leukocyte recruitment and inflammatory lesions in the CNS.
Collapse
Affiliation(s)
- Adriana C Dos Santos
- Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Aryl sulfones as novel Bradykinin B1 receptor antagonists for treatment of chronic pain. Bioorg Med Chem Lett 2008; 18:4764-9. [DOI: 10.1016/j.bmcl.2008.07.108] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2008] [Revised: 07/23/2008] [Accepted: 07/28/2008] [Indexed: 11/22/2022]
|
39
|
Biswas K, Li A, Chen JJ, D'Amico DC, Fotsch C, Han N, Human J, Liu Q, Norman MH, Riahi B, Yuan C, Suzuki H, Mareska DA, Zhan J, Clarke DE, Toro A, Groneberg RD, Burgess LE, Lester-Zeiner D, Biddlecome G, Manning BH, Arik L, Dong H, Huang M, Kamassah A, Loeloff R, Sun H, Hsieh FY, Kumar G, Ng GY, Hungate RW, Askew BC, Johnson E. Potent Nonpeptide Antagonists of the Bradykinin B1 Receptor: Structure−Activity Relationship Studies with Novel Diaminochroman Carboxamides. J Med Chem 2007; 50:2200-12. [PMID: 17408249 DOI: 10.1021/jm070055c] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The bradykinin B1 receptor is induced following tissue injury and/or inflammation. Antagonists of this receptor have been studied as promising candidates for treatment of chronic pain. We have identified aryl sulfonamides containing a chiral chroman diamine moiety that are potent antagonists of the human B1 receptor. Our previously communicated lead, compound 2, served as a proof-of-concept molecule, but suffered from poor pharmacokinetic properties. With guidance from metabolic profiling, we performed structure-activity relationship studies and have identified potent analogs of 2. Variation of the sulfonamide moiety revealed a preference for 3- and 3,4-disubstituted aryl sulfonamides, while bulky secondary and tertiary amines were preferred at the benzylic amine position for potency at the B1 receptor. Modifying the beta-amino acid core of the molecule lead to the discovery of highly potent compounds with improved in vitro pharmacokinetic properties. The most potent analog at the human receptor, compound 38, was also active in a rabbit B1 receptor cellular assay. Furthermore, compound 38 displayed in vivo activity in two rabbit models, a pharmacodynamic model with a blood pressure readout and an efficacy model of inflammatory pain.
Collapse
Affiliation(s)
- Kaustav Biswas
- Department of Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Medeiros R, Passos GF, Vitor CE, Koepp J, Mazzuco TL, Pianowski LF, Campos MM, Calixto JB. Effect of two active compounds obtained from the essential oil of Cordia verbenacea on the acute inflammatory responses elicited by LPS in the rat paw. Br J Pharmacol 2007; 151:618-27. [PMID: 17471174 PMCID: PMC2013990 DOI: 10.1038/sj.bjp.0707270] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND AND PURPOSE alpha-Humulene and trans-caryophyllene are sesquiterpene compounds identified in the essential oil of Cordia verbenacea which display topical and systemic anti-inflammatory effects in different experimental models. However, the molecular mechanisms through which they exert their anti-inflammatory activity still remain unclear. Here, we evaluate the effects of alpha-humulene and trans-caryophyllene on the acute inflammatory responses elicited by LPS. EXPERIMENTAL APPROACH The biological activities of alpha-humulene and trans-caryophyllene were investigated in a model of acute inflammation in rat paw, induced by LPS and characterized by paw oedema, neutrophil recruitment, cytokine production, activation of MAP kinases and NF-kappaB and up-regulated expression of kinin B(1) receptors. KEY RESULTS Treatment with either alpha-humulene or trans-caryophyllene effectively reduced neutrophil migration and activation of NF-kappaB induced by LPS in the rat paw. However, only alpha-humulene significantly reduced the increase in TNF-alpha and IL-1beta levels, paw oedema and the up-regulation of B(1) receptors following treatment with LPS. Both compounds failed to interfere with the activation of the MAP kinases, ERK, p38 and JNK. CONCLUSIONS AND IMPLICATIONS Both alpha-humulene and trans-caryophyllene inhibit the LPS-induced NF-kappaB activation and neutrophil migration, although only alpha-humulene had the ability to prevent the production of pro-inflammatory cytokines TNF-alpha and IL-1beta and the in vivo up-regulation of kinin B(1) receptors. These data provide additional molecular and functional insights into the beneficial effects of the sesquiterpenes alpha-humulene and trans-caryophyllene isolated from the essential oil of Cordia verbenacea as agents for the management of inflammatory diseases.
Collapse
Affiliation(s)
- R Medeiros
- Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina Santa Catarina, Brazil
| | - G F Passos
- Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina Santa Catarina, Brazil
| | - C E Vitor
- Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina Santa Catarina, Brazil
| | - J Koepp
- Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina Santa Catarina, Brazil
| | - T L Mazzuco
- Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina Santa Catarina, Brazil
| | - L F Pianowski
- Rua Setúbal, Residencial Euroville Bragança Paulista, São Paulo, Brazil
| | - M M Campos
- Escola de Odontologia, Pontifícia Universidade Católica do Rio Grande do Sul Rio Grande do Sul, Brazil
| | - J B Calixto
- Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina Santa Catarina, Brazil
- Author for correspondence:
| |
Collapse
|
41
|
Abstract
The bradykinin B1 receptor is an inducible G-protein-coupled receptor. It is induced or upregulated at the site of inflammation or injury. A large body of preclinical data supports the development of B1 antagonists as novel therapeutics for the treatment of pain and inflammation. The necessary in vitro and in vivo drug discovery tools are currently available to evaluate novel B1 antagonists. Two major classes of small-molecule B1 antagonists, arylsulfonamide-based and biphenyl-based B1 antagonists, have been disclosed in the last few years.
Collapse
Affiliation(s)
- Jian Jeffrey Chen
- Amgen Inc., Chemistry Research and Development, One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
| | | |
Collapse
|
42
|
Giusti B, Serratì S, Margheri F, Papucci L, Rossi L, Poggi F, Magi A, Del Rosso A, Cinelli M, Guiducci S, Kahaleh B, Matucci-Cerinic M, Abbate R, Fibbi G, Del Rosso M. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. ACTA ACUST UNITED AC 2005; 52:3618-28. [PMID: 16255054 DOI: 10.1002/art.21383] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Postnatal angiogenesis relies on a proper response of endothelial cells to angiogenic stimuli. In systemic sclerosis (SSc), endothelial cells are unresponsive to angiogenic factors. Since circumstantial and experimental evidence points to tissue kallikreins as powerful effectors of the angiogenic response, we undertook this study to investigate the kallikrein pattern of normal and SSc endothelial cells in order to identify differences that can account for defective angiogenesis. METHODS Expression of 14 tissue kallikreins was studied by a microarray approach, by reverse transcription-polymerase chain reaction, and by Western blotting in endothelial cells isolated from the skin of clinically healthy subjects and SSc patients. Cell proliferation was quantified by direct cell counting. Invasion and capillary morphogenesis were evaluated in a Boyden chamber and in culture flasks layered with Matrigel. Cyclic nucleotide production was measured by enzyme immunoassay. MAP kinase and ERK activation were measured by Western blotting. RESULTS Endothelial cells from SSc patients showed poor expression of kallikreins 9, 11, and 12 compared with endothelial cells from normal subjects. Antibodies against the relevant kallikreins on normal endothelial cells revealed that while kallikreins 9, 11, and 12 induced cell growth, only kallikrein 12 regulated invasion and capillary morphogenesis. Buffering of kallikrein 12 with antibodies resulted in the acquisition of an SSc-like pattern by normal cells in in vitro angiogenesis. Reduction of cAMP and cGMP production and of ERK phosphorylation upon administration of antikallikrein antibodies revealed that the activity of kallikreins 9, 11, and 12 was mediated by kinins. CONCLUSION Reduction of tissue kallikreins 9, 11, and 12 may be relevant to reduced angiogenesis in SSc patients.
Collapse
MESH Headings
- Antibodies, Blocking/pharmacology
- Blotting, Western
- Cell Count
- Cell Proliferation
- Cells, Cultured
- Endothelial Cells/cytology
- Endothelial Cells/drug effects
- Endothelial Cells/metabolism
- Extracellular Signal-Regulated MAP Kinases/metabolism
- Female
- Gene Expression Profiling
- Gene Expression Regulation
- Humans
- Male
- Microcirculation/cytology
- Neovascularization, Pathologic/metabolism
- Neovascularization, Pathologic/pathology
- Nucleotides, Cyclic/metabolism
- Oligonucleotide Array Sequence Analysis
- Phosphorylation
- RNA, Messenger/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Scleroderma, Systemic/metabolism
- Scleroderma, Systemic/pathology
- Scleroderma, Systemic/physiopathology
- Skin/blood supply
- Tissue Kallikreins/genetics
- Tissue Kallikreins/immunology
- Tissue Kallikreins/metabolism
Collapse
Affiliation(s)
- Betti Giusti
- Department of Experimental Pathology and Oncology, University of Florence, Viale G M Morgagni 50, 50134 Florence, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Leeb-Lundberg LMF, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57:27-77. [PMID: 15734727 DOI: 10.1124/pr.57.1.2] [Citation(s) in RCA: 729] [Impact Index Per Article: 38.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Kinins are proinflammatory peptides that mediate numerous vascular and pain responses to tissue injury. Two pharmacologically distinct kinin receptor subtypes have been identified and characterized for these peptides, which are named B1 and B2 and belong to the rhodopsin family of G protein-coupled receptors. The B2 receptor mediates the action of bradykinin (BK) and lysyl-bradykinin (Lys-BK), the first set of bioactive kinins formed in response to injury from kininogen precursors through the actions of plasma and tissue kallikreins, whereas the B(1) receptor mediates the action of des-Arg9-BK and Lys-des-Arg9-BK, the second set of bioactive kinins formed through the actions of carboxypeptidases on BK and Lys-BK, respectively. The B2 receptor is ubiquitous and constitutively expressed, whereas the B1 receptor is expressed at a very low level in healthy tissues but induced following injury by various proinflammatory cytokines such as interleukin-1beta. Both receptors act through G alpha(q) to stimulate phospholipase C beta followed by phosphoinositide hydrolysis and intracellular free Ca2+ mobilization and through G alpha(i) to inhibit adenylate cyclase and stimulate the mitogen-activated protein kinase pathways. The use of mice lacking each receptor gene and various specific peptidic and nonpeptidic antagonists have implicated both B1 and B2 receptors as potential therapeutic targets in several pathophysiological events related to inflammation such as pain, sepsis, allergic asthma, rhinitis, and edema, as well as diabetes and cancer. This review is a comprehensive presentation of our current understanding of these receptors in terms of molecular and cell biology, physiology, pharmacology, and involvement in human disease and drug development.
Collapse
Affiliation(s)
- L M Fredrik Leeb-Lundberg
- Division of Cellular and Molecular Pharmacology, Department of Experimental Medical Science, Lund University, BMC, A12, SE-22184 Lund, Sweden.
| | | | | | | | | |
Collapse
|
44
|
Del Rosso A, Distler O, Milia AF, Emanueli C, Ibba-Manneschi L, Guiducci S, Conforti ML, Generini S, Pignone A, Gay S, Madeddu P, Matucci-Cerinic M. Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis 2005; 64:382-7. [PMID: 15708892 PMCID: PMC1755411 DOI: 10.1136/ard.2004.023382] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND In systemic sclerosis (SSc) the lack of an angiogenic response to hypoxia may be due to inappropriate synthesis of angiogenic and angiostatic factors. Tissue kallikrein (t-kallikrein), regulating the kallikrein-kinin system and acting on the microcirculation, is a potent angiogenic agent, and kallistatin is its natural inhibitor. OBJECTIVE To evaluate, in patients with SSc, t-kallikrein and kallistatin levels and their correlation with clinical features and measures of microvascular involvement. PATIENTS AND METHODS Serum levels of t-kallikrein and kallistatin (ELISA) and t-kallikrein skin expression (immunohistochemistry) were studied in patients with SSc, and evaluated for subset (dSSc or lSSc), clinical and immunological features, and microvascular involvement (ulcers, telangiectasias, nailfold videocapillaroscopy). RESULTS Circulating levels of t-kallikrein were higher in SSc than in controls (p<0.001). T-kallikrein did not differ between lSSc and dSSc, although it was higher in lSSc than in controls (p<0.001).T-kallikrein levels were higher in patients with early and active capillaroscopic pattern than in those with late pattern (p = 0.019 and 0.023). Patients with giant capillaries and capillary microhaemorrhages had higher t-kallikrein concentrations than patients with architectural derangement (p = 0.04). No differences in kallistatin levels were detected between patients with SSc and controls, or between lSSc and dSSc. In early SSc skin, the presence of t-kallikrein was found in endothelial and in perivascular inflammatory cells, while no staining in skin of advanced SSc was detected. CONCLUSION T-kallikrein levels are increased in patients with SSc, particularly in lSSc, and are associated with early and active capillaroscopic patterns. T-kallikrein may play a part in SSc microvascular changes.
Collapse
Affiliation(s)
- A Del Rosso
- Department of Medicine, Division of Rheumatology, University of Florence, Viale G Pieraccini, 18-50139 Florence, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
McLean PG, Perretti M, Ahluwalia A. Kinin B1receptors as novel anti-inflammatory targets. ACTA ACUST UNITED AC 2005. [DOI: 10.1517/14728222.4.2.127] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
46
|
Garle MJ, Fry JR. Sensory nerves, neurogenic inflammation and pain: missing components of alternative irritation strategies? A review and a potential strategy. Altern Lab Anim 2005; 31:295-316. [PMID: 15612874 DOI: 10.1177/026119290303100313] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The eyes and skin are highly innervated by sensory nerves; stimulation of these nerves by irritants may give rise to neurogenic inflammation, leading to sensory irritation and pain. Few in vitro models of neurogenic inflammation have been described in conjunction with alternative skin and eye irritation methods, despite the fact that the sensory innervation of these organs is well-documented. To date, alternative approaches to the Draize skin and eye irritation tests have proved largely successful at classifying severe irritants, but are generally poor at discriminating between agents with mild to moderate irritant potential. We propose that the development of in vitro models for the prediction of sensory stimulation will assist in the re-classification of the irritant potential of agents that are under-predicted by current in vitro strategies. This review describes the range of xenobiotics known to cause inflammation and pain through the stimulation of sensory nerves, as well as the endogenous mediators and receptor types that are involved. In particular, it focuses on the vanilloid receptor, its activators and its regulation, as these receptors function as integrators of responses to numerous noxious stimuli. Cell culture models and ex vivo preparations that have the potential to serve as predictors of sensory irritation are also described. In addition, as readily available sensory neuron cell line models are few in number, stem cell lines (with the capacity to differentiate into sensory neurons) are explored. Finally, a preliminary strategy to enable assessment of whether incorporation of a sensory component will enhance the predictive power of current in vitro eye and skin testing strategies is proposed.
Collapse
Affiliation(s)
- Michael J Garle
- Division of Gastroenterology, School of Medical and Surgical Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK
| | | |
Collapse
|
47
|
Chopra B, Barrick SR, Meyers S, Beckel JM, Zeidel ML, Ford APDW, de Groat WC, Birder LA. Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. J Physiol 2005; 562:859-71. [PMID: 15576455 PMCID: PMC1665539 DOI: 10.1113/jphysiol.2004.071159] [Citation(s) in RCA: 104] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2004] [Accepted: 11/29/2004] [Indexed: 12/29/2022] Open
Abstract
The bladder urothelium exhibits dynamic sensory properties that adapt to changes in the local environment. These studies investigated the localization and function of bradykinin receptor subtypes B1 and B2 in the normal and inflamed (cyclophosphamide (CYP)-induced cystitis) bladder urothelium and their contribution to lower urinary tract function in the rat. Our findings indicate that the bradykinin 2 receptor (B2R) but not the bradykinin 1 receptor (B1R) is expressed in control bladder urothelium. B2R immunoreactivity was localized throughout the bladder, including the urothelium and detrusor smooth muscle. Bradykinin-evoked activation of this receptor elevated intracellular calcium (EC(50) = 8.4 nM) in a concentration-related manner and evoked ATP release from control cultured rat urothelial cells. In contrast, B1R mRNA was not detected in control rat urinary bladder; however, following acute (24 h) and chronic (8 day) CYP-induced cystitis in the rat, B1R mRNA was detected throughout the bladder. Functional B1Rs were demonstrated by evoking ATP release and increases in [Ca(2+)](i) in CYP (24 h)-treated cultured rat urothelial cells with a selective B1 receptor agonist (des-Arg(9)-bradykinin). Cystometry performed on control anaesthetized rats revealed that intravesical instillation of bradykinin activated the micturition pathway. Attenuation of this response by the P2 receptor antagonist PPADS suggests that bradykinin-induced micturition facilitation may be due in part to increased purinergic responsiveness. CYP (24 h)-treated rats demonstrated bladder hyperactivity that was significantly reduced by intravesical administration of either B1 (des-Arg(10)-Hoe-140) or B2 (Hoe-140) receptor antagonists. These studies demonstrate that urothelial expression of bradykinin receptors is plastic and is altered by pathology.
Collapse
Affiliation(s)
- Bikramjit Chopra
- A1207 Scaife Hall, Department of Medicine-Renal Division, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Piserchio A, Zelesky V, Yu J, Taylor L, Polgar P, Mierke DF. Bradykinin B2 receptor signaling: Structural and functional characterization of the C-terminus. Biopolymers 2005; 80:367-73. [PMID: 15682437 DOI: 10.1002/bip.20220] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Over the last few years the importance of the intracellular C-terminus in the signaling of G-protein coupled receptors (GPCR) has become increasingly evident. In an effort to provide a structural framework for biological function, we have determined the conformation of the C-terminus of the bradykinin (BK) B2 receptor. Using a uniformly 15N- and 13C-enriched sample of the BKB2 receptor [309-366], NMR results clearly define three alpha-helices lying on the zwitterionic surface of the dodecylphosphocholine. The proximal helix consisting of residues 311-326 was previously predicted based on homology modeling with rhodopsin. This corresponds to what is often called helix-8 of the GPCRs. The two distal helices, residues 333-345 and 348-363, are clearly borne out by the NMR data. The functional importance of these secondary structural elements was probed by determination of the signaling properties (inositol phosphate formation) of mutant BKB2 receptors lacking the domains (deletion mutants) or containing the corresponding region from the related GPCR, angiotensin II AT1a (chimera receptors). We demonstrate that the regions between the helices (residues 327-333 and 346-347) can be exchanged without loss of signaling. In contrast, modification of the three helices, particularly the hydroxyl-containing residues, has drastic effects on the signaling profile of the BKB2 receptor. By coupling of the structural features with the functional data, the molecular mechanisms of signaling by the BKB2 receptor are beginning to be established.
Collapse
Affiliation(s)
- Andrea Piserchio
- Department of Molecular Pharmacology, Division of Biology & Medicine, Brown University, Providence, RI 02912, USA
| | | | | | | | | | | |
Collapse
|
49
|
Entschladen F, Drell TL, Palm D, Bastian P, Potthoff S, Zänker KS, Lang K. A comparative review on leukocyte and tumor cell migration with regard to the regulation by serpentine receptor ligands. ACTA ACUST UNITED AC 2004. [DOI: 10.1002/sita.200400036] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
50
|
Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, Campos MM. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004; 143:803-18. [PMID: 15520046 PMCID: PMC1575942 DOI: 10.1038/sj.bjp.0706012] [Citation(s) in RCA: 195] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2004] [Revised: 08/03/2004] [Accepted: 09/10/2004] [Indexed: 01/25/2023] Open
Abstract
Kinins are a family of peptides implicated in several pathophysiological events. Most of their effects are likely mediated by the activation of two G-protein-coupled receptors: B(1) and B(2). Whereas B(2) receptors are constitutive entities, B(1) receptors behave as key inducible molecules that may be upregulated under some special circumstances. In this context, several recent reports have investigated the importance of B(1) receptor activation in certain disease models. Furthermore, research on B(1) receptors in the last years has been mainly focused in determining the mechanisms and pathways involved in the process of induction. This was essentially favoured by the advances obtained in molecular biology studies, as well as in the design of selective and stable peptide and nonpeptide kinin B(1) receptor antagonists. Likewise, development of kinin B(1) receptor knockout mice greatly helped to extend the evidence about the relevance of B(1) receptors during pathological states. In the present review, we attempted to remark the main advances achieved in the last 5 years about the participation of kinin B(1) receptors in painful and inflammatory disorders. We have also aimed to point out some groups of chronic diseases, such as diabetes, arthritis, cancer or neuropathic pain, in which the strategic development of nonpeptidic oral-available and selective B(1) receptor antagonists could have a potential relevant therapeutic interest.
Collapse
Affiliation(s)
- João B Calixto
- Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, 88049-900 Florianópolis, SC, Brazil.
| | | | | | | | | | | |
Collapse
|